/
Biological products, (no diagnostic substances) company · DE · FY ends Mar · Revenue $142K · -8066.20% margin · -$11M FCF
The business is unprofitable at the operating level (-8761.11% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 32.1% YoY with margins expanding 5079.3pp.
ROIC dropped from -107.71% to -121.33%, capital efficiency is deteriorating. Negative free cash flow of -$9M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$142K
▲ +32.1% YoY
Net Income (TTM)
-$1M
▲ +83.0% YoY
Op. Margin
-8066.20%
▲ +5079.3pp YoY
ROIC
-104.68%
▼ -13.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$11M
▲ +35.5% YoY
Op. Cash Flow (TTM)
-$11M
▲ +35.4% YoY
Net Debt
-$4M
Net Cash Position
Cash & Equiv.
$4M
5Y CAGR: -42.0%
Continue Research